Harnessing Genome-wide Association Studies to Minimize Adverse Radiation-induced Side Effects

Overview

Journal Radiat Oncol J

Specialty Oncology

Date 2020 Nov 24

PMID 33233031

Citations 5

Authors

Cecil M Benitez

Susan J Knox

Affiliations

Soon will be listed here.

Abstract

Radiotherapy is used as definitive treatment in approximately two-thirds of all cancers. However, like any treatment, radiation has significant acute and long-term side effects including secondary malignancies. Even when similar radiation parameters are used, 5%-10% of patients will experience adverse radiation side effects. Genomic susceptibility is thought to be responsible for approximately 40% of the clinical variability observed. In the era of precision medicine, the link between genetic susceptibility and radiation-induced side effects is further strengthening. Genome-wide association studies (GWAS) have begun to identify single-nucleotide polymorphisms (SNPs) attributed to overall and tissue-specific toxicity following radiation for treatment of breast cancer, prostate cancer, and other cancers. Here, we review the use of GWAS in identifying polymorphisms that are predictive of acute and long-term radiation-induced side effects with a focus on chest, pelvic, and head-and-neck irradiation. Integration of GWAS studies with "omic" data, patient characteristics, and clinical correlates into predictive models could decrease radiation-induced side effects while increasing therapeutic efficacy.

Citing Articles

A Case Report on Radiation-Induced Cerebral Vasculopathy in a Long-Term Survivor of Childhood Medulloblastoma.

Esteves S, Szymanski K, Kuwabara M Cureus. 2024; 16(8):e68213.

PMID: 39347355 PMC: 11439436. DOI: 10.7759/cureus.68213.

Baseline DSB repair prediction of chronic rare Grade ≥ 3 toxicities induced by radiotherapy using classification algorithms.

Muggiolu G, Sauvaigo S, Libert S, Millet M, Daguenet E, Bouleftour W J Radiat Res. 2024; 65(4):540-548.

PMID: 38899572 PMC: 11262860. DOI: 10.1093/jrr/rrae047.

Molecular Biomarkers in Cancer.

Sarhadi V, Armengol G Biomolecules. 2022; 12(8).

PMID: 35892331 PMC: 9331210. DOI: 10.3390/biom12081021.

Proton beam therapy with concurrent chemotherapy is feasible in children with newly diagnosed rhabdomyosarcoma.

Suzuki R, Fukushima H, Okuwaki H, Inaba M, Hosaka S, Yamaki Y Rep Pract Oncol Radiother. 2021; 26(4):616-625.

PMID: 34434578 PMC: 8382069. DOI: 10.5603/RPOR.a2021.0082.

Artificial Intelligence and Precision Medicine: A Perspective.

Lorkowski J, Kolaszynska O, Pokorski M Adv Exp Med Biol. 2021; 1375:1-11.

PMID: 34138457 DOI: 10.1007/5584_2021_652.

References

Rattay T, Talbot C . Finding the genetic determinants of adverse reactions to radiotherapy. Clin Oncol (R Coll Radiol). 2014; 26(5):301-8. DOI: 10.1016/j.clon.2014.02.001. View

Alam A, Mukhopadhyay N, Ning Y, Reshko L, Cardnell R, Alam O . A Preliminary Study on Racial Differences in HMOX1, NFE2L2, and TGFβ1 Gene Polymorphisms and Radiation-Induced Late Normal Tissue Toxicity. Int J Radiat Oncol Biol Phys. 2015; 93(2):436-43. PMC: 4575610. DOI: 10.1016/j.ijrobp.2015.05.049. View

Du L, Yu W, Dai X, Zhao N, Huang X, Tong F . Association of DNA repair gene polymorphisms with the risk of radiation pneumonitis in lung cancer patients. Oncotarget. 2018; 9(1):958-968. PMC: 5787526. DOI: 10.18632/oncotarget.22982. View

Herskind C, Talbot C, Kerns S, Veldwijk M, Rosenstein B, West C . Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?. Cancer Lett. 2016; 382(1):95-109. PMC: 5016239. DOI: 10.1016/j.canlet.2016.02.035. View

Wojcik G, Graff M, Nishimura K, Tao R, Haessler J, Gignoux C . Genetic analyses of diverse populations improves discovery for complex traits. Nature. 2019; 570(7762):514-518. PMC: 6785182. DOI: 10.1038/s41586-019-1310-4. View

Hanania A, Mainwaring W, Ghebre Y, Hanania N, Ludwig M . Radiation-Induced Lung Injury: Assessment and Management. Chest. 2019; 156(1):150-162. PMC: 8097634. DOI: 10.1016/j.chest.2019.03.033. View

Kang J, Coates J, Strawderman R, Rosenstein B, Kerns S . Genomics models in radiotherapy: From mechanistic to machine learning. Med Phys. 2020; 47(5):e203-e217. PMC: 8725063. DOI: 10.1002/mp.13751. View

Yang D, Wang T, Zhang J, Li X, He Y, Xiao R . Genome-wide association study identifies genetic susceptibility loci and pathways of radiation-induced acute oral mucositis. J Transl Med. 2020; 18(1):224. PMC: 7275566. DOI: 10.1186/s12967-020-02390-0. View

Ahmed M, Dorling L, Kerns S, Fachal L, Elliott R, Partliament M . Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. Br J Cancer. 2016; 114(10):1165-74. PMC: 4865979. DOI: 10.1038/bjc.2016.94. View

10.

El Naqa I, Kerns S, Coates J, Luo Y, Speers C, West C . Radiogenomics and radiotherapy response modeling. Phys Med Biol. 2017; 62(16):R179-R206. PMC: 5557376. DOI: 10.1088/1361-6560/aa7c55. View

11.

Rosenstein B . Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity. Semin Radiat Oncol. 2017; 27(4):300-309. PMC: 5657449. DOI: 10.1016/j.semradonc.2017.04.005. View

12.

Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M . Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019; 394(10196):385-395. DOI: 10.1016/S0140-6736(19)31131-6. View

13.

Chang-Claude J, Popanda O, Tan X, Kropp S, Helmbold I, von Fournier D . Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res. 2005; 11(13):4802-9. DOI: 10.1158/1078-0432.CCR-04-2657. View

14.

Morton L, Sampson J, Armstrong G, Chen T, Hudson M, Karlins E . Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. J Natl Cancer Inst. 2017; 109(11). PMC: 6059172. DOI: 10.1093/jnci/djx058. View

15.

Fachal L, Gomez-Caamano A, Barnett G, Peleteiro P, Carballo A, Calvo-Crespo P . A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat Genet. 2014; 46(8):891-4. DOI: 10.1038/ng.3020. View

16.

Kelsey C, Broadwater G, James O, Chino J, Diehl L, Beaven A . Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019; 105(1):96-101. PMC: 10171462. DOI: 10.1016/j.ijrobp.2019.02.055. View

17.

Kerns S, De Ruysscher D, Andreassen C, Azria D, Barnett G, Chang-Claude J . STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiother Oncol. 2013; 110(1):182-8. PMC: 4786020. DOI: 10.1016/j.radonc.2013.07.011. View

18.

Cheng Y, Nie X, Ji C, Lin X, Liu L, Chen X . Long-Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer. J Am Heart Assoc. 2017; 6(5). PMC: 5524103. DOI: 10.1161/JAHA.117.005633. View

19.

Lee S, Kerns S, Ostrer H, Rosenstein B, Deasy J, Oh J . Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018; 101(1):128-135. PMC: 5886789. DOI: 10.1016/j.ijrobp.2018.01.054. View

20.

Barnett G, Thompson D, Fachal L, Kerns S, Talbot C, Elliott R . A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol. 2014; 111(2):178-85. DOI: 10.1016/j.radonc.2014.02.012. View